Novel drug development through drug repurposing

Biomedicine & Pharmacotherapy
Volume 110, February 2019, Pages 700-716

Drug Repurposing

  • Drug repurposing involves identification of new indications for pre-marketed drugs that were unfruitful for reasons other than clinical safety. This radical approach saves time for searching new active ingredients, saving 25~35% of development costs. Furthermore, market distribution can be accelerated due to clinical success rates that are 2.5 times higher than conventional drugs (10%). This is achieved by drastically reducing patient exposure to potential safety and pharmacokinetic risks.

Drug repurposing

DWRX2004

Summary

DWRX2004 is a new drug repurposed from existing commercial drugs for new indications.
It is developed as a treatment for rotator cuff tear(RCT).

Mechanism: FABP4 inhibitor

Charateristics:

  1. Development of non-surgical treatment for rotator cuff tear (First-in-disease)
  2. Confirmed FABP4 inhibtion in C2CL12 (mouse myoblast cell line) in-vivo
  3. Confirmed intramyocellular lipid accumulation reduction by about 85% compared to the control in vivo

Development Plan: IND submission in 2021 and begin Phase 1 clinical trial in 2022

DWRX2005

Summary

DWRX2004 is a new drug repurposed from existing commercial drugs for new indications.
It is developed as a treatment for pulmonary arterial hypertension(PAH) and other various indications.

Mechanism: TMEM16A inhibitor

Characteristics:

  1. Confirmed blood pressure reduction and improved mortality in-vivo
  2. Confirmed inhibitory effect of STAT3 phosphorylation in lung tissue in-vivo
  3. Confirmed right ventricular hypertrophy suppression in-vivo

Development plan: begin Phase 1 clinical trial in 2020